In breast cancer (BC), the efficacy results of the PARPi olaparib (Lynparza®) in metastatic patients carrying a germline BRCA1/2 (gBRCA) pathogenic variant have led to its recent approval by the Food and Drug Administration (Robson et al, 2017). This evidence concerns the gene BRCA1 and breast carcinoma.